(iv) sequences having at least 90% identity to SEQ ID NO:198; and

(b) a diagnostic reagent for use in a polymerase chain reaction or hybridization assay.

REMARKS

Claims 5, 14-16 and 26 have been cancelled from the application and Claims 3, 13, 22, and 65 have been amended. Support for all the above amendments may be found throughout the specification as originally filed and none of the amendments constitute new matter.

Following this amendment, Claims 3-8, 13, 22 and 65 are thus currently under examination. Favorable consideration of the present application in view of the above amendment is respectfully requested.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Jeffrey Hundley
Registration No. 42,676

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

Wpn/210121/484C3/-PrelimAmend

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

Claims 5, 14-16 and 26 have been cancelled.

Claims 3, 13, 22 and 65 have been amended as follows:

3. (Amended) An isolated polynucleotide comprising a sequence selected from the group consisting of:

(a) the polynucleotides recited in ~~any one of~~ SEQ ID NOs:~~1, 2, 5, 9, 10, 13, 16, 19, 23, 27, 28, 32, 33, 35, 38, 41-50, 52, 53, 57, 63, 65, 69-72, 75, 78, 81, 82, 84, 86, 89-93, 95, 97-100, 103, 107, 111, 114, 117, 120, 121, 125, 128, 132-134, 136, 137, 143-146, 148-151, 156, 158, 160-162, 166-168 or 171, 174-183, 185, 193, 194~~198; ~~and~~

(b) complements of the foregoing polynucleotides;

(c) sequences consisting of at least 50 contiguous residues of SEQ ID NO:198; and

(d) sequences having at least 90% identity to SEQ ID NO:198.

13. (Amended) A ~~pharmaceutical~~ composition comprising:

(a) ~~a~~ an isolated polynucleotide comprising a ~~encoding an ovarian carcinoma polypeptide, wherein the polypeptide comprises at least an immunogenic portion of an ovarian carcinoma protein or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera is not substantially diminished, wherein the ovarian carcinoma protein comprises an amino acid sequence that is encoded by a polynucleotide~~ sequence selected from the group consisting of:

(i) the polynucleotides recited in ~~any one of~~ SEQ ID NOs:~~1, 2, 5, 9, 10, 13, 16, 19, 23, 27, 28, 32, 33, 35, 38, 41-50, 52, 53, 56, 57, 63, 65, 69-72, 75, 78, 80-82, 84, 86, 89-93, 95, 97-100, 103, 107, 111, 114, 117, 120, 121, 125, 128, 132-134, 136, 137, 140, 143-146, 148-151, 156, 158, 160-162, 166-168, 171, 174-183, 185, 193, 194~~198; ~~and~~

(ii) complements of the foregoing polynucleotides; ~~and~~

(iii) sequences consisting of at least 50 contiguous residues of

SEQ ID NO:198; and

(iv) sequences having at least 90% identity to SEQ ID NO:198; and

(b) a physiologically acceptable carrier.

22. (Amended) An isolated polynucleotide encoding a fusion protein ~~according to claim 21~~wherein said polynucleotide comprises a sequence selected from the group consisting of:

(a) the polynucleotide recited in SEQ ID NO:198;

(b) complements of the foregoing polynucleotide;

(c) sequences consisting of at least 50 contiguous residues of SEQ ID NO:198; and

(d) sequences having at least 90% identity to SEQ ID NO:198.

65. (Amended) A diagnostic kit, comprising:

(a) an oligonucleotide comprising 10 to 40 nucleotides that hybridize under moderately stringent conditions to a polynucleotide comprising a ~~that encodes an ovarian carcinoma protein, wherein the ovarian carcinoma protein comprises an amino acid sequence that is encoded by a polynucleotide~~ sequence selected from the group consisting of:

(i) the polynucleotide recited in ~~any one of~~ SEQ ID NOs:~~1-185 and 187-199~~198; ~~and~~

(ii) complements of the foregoing polynucleotides; ~~and~~

(iii) sequences consisting of at least 50 contiguous residues of SEQ ID NO:198; and

(iv) sequences having at least 90% identity to SEQ ID NO:198; and

(b) a diagnostic reagent for use in a polymerase chain reaction or hybridization assay.